Adaptive drug licensing: A chance for patients?
In recent years, various options have been discussed to accelerate the approval of new drugs, especially for conditions with high unmet needs. There is a trade-off between the earlier availability of new treatment options and a potentially higher safety risk of drugs which have not been investigated...
Gespeichert in:
| Veröffentlicht in: | Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen Fortbildung und Qualität im Gesundheitswesen, 2016, Vol.112 Suppl 1, p.S27-S33 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S33 |
|---|---|
| container_issue | |
| container_start_page | S27 |
| container_title | Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen |
| container_volume | 112 Suppl 1 |
| creator | Paar, W Dieter |
| description | In recent years, various options have been discussed to accelerate the approval of new drugs, especially for conditions with high unmet needs. There is a trade-off between the earlier availability of new treatment options and a potentially higher safety risk of drugs which have not been investigated in long-lasting clinical trials and a broader patient population. It must also be taken into account that clinical trial data and results must be sufficient to allow for the reimbursement of the new treatment option. The difficult process of weighting the benefits against the potential risks of an accelerated drug approval should be discussed between patients, regulatory authorities, HTA institutions and pharmaceutical companies. Patients might benefit from a fair, balanced accelerated approval. |
| doi_str_mv | 10.1016/j.zefq.2016.04.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1798992929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1798992929</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-41e9516e6e3f74285d945e92a8550a2988cf775cad1334862aac368c43c9a743</originalsourceid><addsrcrecordid>eNo1j0tLw0AUhQdBbK3-AReSpZukM3febiSU-oCCm-7DOLmpU_JqJhH01xuwchbfWXwcOITcMZoxytT6mP1gdcpg7hkVGWX0giwBGKQUjF2Q6xiPlCrgSl6RBWgOlIJcknVeun4MX5iUw3RI6uCxjaE9PCZ54j9d6zGpuiHp3RiwHePTDbmsXB3x9swV2T9v95vXdPf-8rbJd2nPBBtTwdBKplAhr7QAI0srJFpwRkrqwBrjK62ldyXjXBgFznmujBfcW6cFX5GHv9l-6E4TxrFoQvRY167FbooF09ZYC3Nm9f6sTh8NlkU_hMYN38X_R_4Le_xQHQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1798992929</pqid></control><display><type>article</type><title>Adaptive drug licensing: A chance for patients?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Paar, W Dieter</creator><creatorcontrib>Paar, W Dieter</creatorcontrib><description>In recent years, various options have been discussed to accelerate the approval of new drugs, especially for conditions with high unmet needs. There is a trade-off between the earlier availability of new treatment options and a potentially higher safety risk of drugs which have not been investigated in long-lasting clinical trials and a broader patient population. It must also be taken into account that clinical trial data and results must be sufficient to allow for the reimbursement of the new treatment option. The difficult process of weighting the benefits against the potential risks of an accelerated drug approval should be discussed between patients, regulatory authorities, HTA institutions and pharmaceutical companies. Patients might benefit from a fair, balanced accelerated approval.</description><identifier>EISSN: 2212-0289</identifier><identifier>DOI: 10.1016/j.zefq.2016.04.010</identifier><identifier>PMID: 27320025</identifier><language>ger</language><publisher>Netherlands</publisher><subject>Drug Approval ; Germany ; Humans ; Licensure, Pharmacy</subject><ispartof>Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2016, Vol.112 Suppl 1, p.S27-S33</ispartof><rights>Copyright © 2016. Published by Elsevier GmbH.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27320025$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paar, W Dieter</creatorcontrib><title>Adaptive drug licensing: A chance for patients?</title><title>Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen</title><addtitle>Z Evid Fortbild Qual Gesundhwes</addtitle><description>In recent years, various options have been discussed to accelerate the approval of new drugs, especially for conditions with high unmet needs. There is a trade-off between the earlier availability of new treatment options and a potentially higher safety risk of drugs which have not been investigated in long-lasting clinical trials and a broader patient population. It must also be taken into account that clinical trial data and results must be sufficient to allow for the reimbursement of the new treatment option. The difficult process of weighting the benefits against the potential risks of an accelerated drug approval should be discussed between patients, regulatory authorities, HTA institutions and pharmaceutical companies. Patients might benefit from a fair, balanced accelerated approval.</description><subject>Drug Approval</subject><subject>Germany</subject><subject>Humans</subject><subject>Licensure, Pharmacy</subject><issn>2212-0289</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j0tLw0AUhQdBbK3-AReSpZukM3febiSU-oCCm-7DOLmpU_JqJhH01xuwchbfWXwcOITcMZoxytT6mP1gdcpg7hkVGWX0giwBGKQUjF2Q6xiPlCrgSl6RBWgOlIJcknVeun4MX5iUw3RI6uCxjaE9PCZ54j9d6zGpuiHp3RiwHePTDbmsXB3x9swV2T9v95vXdPf-8rbJd2nPBBtTwdBKplAhr7QAI0srJFpwRkrqwBrjK62ldyXjXBgFznmujBfcW6cFX5GHv9l-6E4TxrFoQvRY167FbooF09ZYC3Nm9f6sTh8NlkU_hMYN38X_R_4Le_xQHQ</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>Paar, W Dieter</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>2016</creationdate><title>Adaptive drug licensing: A chance for patients?</title><author>Paar, W Dieter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-41e9516e6e3f74285d945e92a8550a2988cf775cad1334862aac368c43c9a743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2016</creationdate><topic>Drug Approval</topic><topic>Germany</topic><topic>Humans</topic><topic>Licensure, Pharmacy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paar, W Dieter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paar, W Dieter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adaptive drug licensing: A chance for patients?</atitle><jtitle>Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen</jtitle><addtitle>Z Evid Fortbild Qual Gesundhwes</addtitle><date>2016</date><risdate>2016</risdate><volume>112 Suppl 1</volume><spage>S27</spage><epage>S33</epage><pages>S27-S33</pages><eissn>2212-0289</eissn><abstract>In recent years, various options have been discussed to accelerate the approval of new drugs, especially for conditions with high unmet needs. There is a trade-off between the earlier availability of new treatment options and a potentially higher safety risk of drugs which have not been investigated in long-lasting clinical trials and a broader patient population. It must also be taken into account that clinical trial data and results must be sufficient to allow for the reimbursement of the new treatment option. The difficult process of weighting the benefits against the potential risks of an accelerated drug approval should be discussed between patients, regulatory authorities, HTA institutions and pharmaceutical companies. Patients might benefit from a fair, balanced accelerated approval.</abstract><cop>Netherlands</cop><pmid>27320025</pmid><doi>10.1016/j.zefq.2016.04.010</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 2212-0289 |
| ispartof | Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2016, Vol.112 Suppl 1, p.S27-S33 |
| issn | 2212-0289 |
| language | ger |
| recordid | cdi_proquest_miscellaneous_1798992929 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Drug Approval Germany Humans Licensure, Pharmacy |
| title | Adaptive drug licensing: A chance for patients? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T09%3A01%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adaptive%20drug%20licensing:%20A%20chance%20for%20patients?&rft.jtitle=Zeitschrift%20fu%CC%88r%20Evidenz,%20Fortbildung%20und%20Qualita%CC%88t%20im%20Gesundheitswesen&rft.au=Paar,%20W%20Dieter&rft.date=2016&rft.volume=112%20Suppl%201&rft.spage=S27&rft.epage=S33&rft.pages=S27-S33&rft.eissn=2212-0289&rft_id=info:doi/10.1016/j.zefq.2016.04.010&rft_dat=%3Cproquest_pubme%3E1798992929%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1798992929&rft_id=info:pmid/27320025&rfr_iscdi=true |